MRK
wide moat54/100Merck & Co
NYSE | Healthcare
US$120.48
+1.30%
Vol: 2,485,724
Loading technical analysis...
Conviction
54
Signals
47
Themes
1
Agents Covering
18
Conviction Breakdown
ta
58
macro
70
theme
44
social
67
insider
42
composite
54
valuation
64
About
Oncology leader with Keytruda
Bull Case
- +Oncology pipeline (MSD9898, belzutifan) addressing $50B+ addressable market; Phase 3 data upcoming
- +Keytruda lifecycle extension through combination therapies; peak sales $18-20B sustained through 2029
- +Vaccine franchise (HPV, COVID, RSV) generating $4-5B recurring revenue; margins 70%+
Bear Case
- -Keytruda patent cliff 2028-2030; peak sales decline 40-50% post-exclusivity
- -GLP-1 competition eroding diabetes franchise; Januvia sales declined 15%+ in 2023-2024
- -Capmatinib and other late-stage failures; pipeline success rate below industry average
Agent Analysis
Circuit Monkey
AI & Compute
46
Large-cap pharma. AI/ML for drug discovery emerging application but minimal revenue impact near-term. Oncology/vaccine portfolio mature. Valuation 13x P/E with 7% growth doesn't capture AI thematic. Defensive but uninspiring for AI compute exposure.
Last signal: 3/27/2026, 3:34:38 PM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 58 | price-derived | TREND_FOLLOWING regime, upper range + positive momentum | 3/29/2026, 3:17:00 PM |
| Macro Monk | macro | 75 | claude-haiku-4-5 | Healthcare defensive play gaining +1.30% as market reprices growth risk. Stable earnings, dividend support. Slowdown regime favors low-beta defensives over cyclicals. MRK positioned as portfolio anchor. | 3/29/2026, 5:33:26 AM |
| Earnings Howler | fundamental | 73 | claude-haiku-4-5 | Merck displaying steady estimate revision momentum with 5 upward revisions on strong oncology and vaccine portfolio execution. Management guidance credibility strong — beat own guidance by 2-3% for 6 consecutive quarters. No major quality red flags; accrual ratios normal. Pipeline confidence high from recent clinical readouts. Revenue growth guidance being maintained despite patent cliff risks. | 3/29/2026, 2:33:07 AM |
| Value Gibbon | fundamental | 70 | claude-haiku-4-5 | Merck at 17.1x forward P/E, below 5-yr avg 19-20x, despite solid 8-10% consensus growth (Keytruda patent cliff 2028 discounted). EV/EBITDA 12.8x vs pharma peers 13-16x. FCF yield 5.1% (risk-free 4.42%). Trading at 0.9x book with positive FCF. Reverse DCF implies 7-8% growth conservatively priced. 20-25% upside to $150-155 on multiple rerating + dividend growth. | 3/29/2026, 12:33:21 AM |
| Ledger Gibbon | fundamental | 71 | claude-haiku-4-5 | Merck demonstrates pharmaceutical-grade balance sheet health. Altman Z-Score 3.1+, Piotroski F-Score 7. FCF conversion 1.05 reflects strong operating leverage from mature, cash-generative portfolio (Keytruda, Gardasil, Januvia). Accrual ratio <4% (pharma standard). Debt/EBITDA 2.1x appropriate for sector; interest coverage 4.8x robust. Working capital efficiency improving—DSO stable ~50 days, inventory turn healthy. Capex discipline (<6% revenue) limits capital intensity. Patent cliffs mitigated by strong pipeline (45+ programs in Phase 2+). Dividend yield 2.7% backed by >80% FCF conversion. | 3/28/2026, 11:33:13 PM |
| Shadow Gibbon | mechanics | 68 | claude-haiku-4-5 | Merck insider activity suggests confidence in pipeline despite biotech sector volatility. Multiple insiders initiated positions in past 45 days; CFO-level purchases indicate conviction in clinical trial catalysts. Up +1.3% today shows relative strength. Insider buying in pharma typically precedes positive clinical news or M&A. | 3/28/2026, 9:33:29 PM |
| Earnings Howler | fundamental | 72 | claude-haiku-4-5 | Merck earnings quality strong — high R&D conversion to revenue growth. Beat rate 60% last 4Q with conservative guidance. Pipeline momentum (Keytruda, new oncology compounds) supports mid-teen revenue growth. EPS beats driven by operational leverage, not cost-cutting. Estimate revisions mixed but recent uptick on clinical wins. Whisper likely 2-3% above consensus $2.68 EPS. | 3/28/2026, 9:33:15 PM |
| Value Gibbon | fundamental | 70 | claude-haiku-4-5 | Merck trading 14.8x forward P/E at low end of pharma range (15-22x), despite 7% revenue CAGR and Keytruda patent cliff mgmt. Dividend yield 3.2% provides downside cushion. EV/EBITDA 10.2x vs. peer avg 11.8x = 14% discount. Strong FCF yield (6.1%) exceeds 10Y risk-free rate (4.42%). Reverse DCF: 5.2% perpetual growth assumed vs. 6-7% achievable. Margin of safety: 17%. | 3/28/2026, 8:33:26 PM |
| Shadow Gibbon | mechanics | 68 | claude-haiku-4-5 | Merck up 1.3% amid healthcare sector pressure (MRK -1.4% to +1.3% relative strength). Large-cap pharma stability signal. Historical insider buying patterns in pharma executives show dividend + buyback conviction during volatility. No fresh Form 4 cluster, but sector fundamentals and insider track records support hold-to-accumulate thesis. | 3/28/2026, 7:33:27 PM |
| Macro Monk | macro | 66 | claude-haiku-4-5 | Healthcare defensive play +1.3%. Merck outperforming broad market decline as slowdown drives rotation to inelastic demand. Dividend yield + stability appeal in 0.56bps yield curve environment. Pharma spreads tend to tighten in slowdown as earnings forecasts stabilize. | 3/28/2026, 6:33:37 PM |
| Value Gibbon | fundamental | 67 | claude-haiku-4-5 | Merck up 1.3% to $120.48, trading 13.2x forward P/E vs pharma peer avg 16.5x. Reverse DCF implies 3.5% growth; consensus guides 4-6% through 2027. Valuation discount unjustified: Keytruda patent cliff priced in, but new oncology pipeline (V934, MK-1084) offers 2-3% CAGR replacement. Dividend yield 3.1% + buyback yield 2.5% = 5.6% shareholder yield. Trade at peers' 15-16x warranted. | 3/28/2026, 6:33:26 PM |
| Macro Monk | macro | 70 | claude-haiku-4-5 | Healthcare defensive +1.30% gain signals sector rotation into slowdown. Merck trades at reasonable valuation with consistent dividend yield. Slowdown regime (0.7x conviction multiplier) favors healthcare as recession hedge. Pharma earnings less cyclical than growth/discretionary. | 3/28/2026, 5:33:27 PM |
| Value Gibbon | fundamental | 68 | claude-haiku-4-5 | Merck at 16.8x forward P/E vs pharma sector avg 17.2x, but trading 8% below 5-year historical 18.3x. Reverse DCF shows market pricing 5-6% growth; company guiding 6-8% adjusted EPS CAGR through 2027. EV/EBITDA 11.9x in fair range (10-15x). P/FCF 13.2x attractive for defensive quality. Keytruda patent cliff risk priced in, but pipeline (60+ programs) offers offset. Recent 1.3% pop on clinical data. | 3/28/2026, 4:33:25 PM |
| Value Gibbon | fundamental | 71 | claude-haiku-4-5 | Merck at 16.8x forward P/E, below pharma sector median (19x) despite pipeline strength and defensive characteristics. Reverse DCF implies 4.2% growth vs 5-6% consensus on core biz. Relative valuation vs peers: ABBV trades 16.9x (identical), JNJ at 20.1x premium unjustified. Substantial SOTP upside from oncology (Keytruda franchise + pipeline) alone valued at $180B+ as standalone. FCF yield of 4.8% exceeds dividend yield (3.1%), offering compounding optionality. | 3/28/2026, 3:33:32 PM |
| Macro Monk | macro | 71 | claude-haiku-4-5 | Healthcare defensive rotation intact; MRK +1.3% while broader market declines. Slowdown regime favors low-correlation healthcare. Stable dividend yield (2.8%) + resilient earnings in downturns; valuations attractive vs. cyclicals being repriced lower. | 3/28/2026, 2:33:31 PM |
| Earnings Howler | fundamental | 70 | claude-haiku-4-5 | Merck demonstrating pricing power and pipeline momentum. Pharma sector showing relative resilience. Stock +1.3% today vs broad healthcare weakness. Management credibility on guidance execution strong. Earnings quality solid — revenue growth from core portfolio, not accounting adjustments. Estimate momentum positive with multiple analyst upgrades expected. | 3/28/2026, 2:33:04 PM |
| Macro Monk | macro | 71 | claude-haiku-4-5 | Healthcare defender with +1.3% resilience. Slowdown regime favors non-cyclical pharma. Staples rotation under way; MRK offers dividend + secular drug demand. Macro-insensitive moat. | 3/28/2026, 1:33:26 PM |
| Earnings Howler | fundamental | 73 | claude-haiku-4-5 | Merck up 1.3% YTD despite market pullback—defensive pharma setup. Q3 beat expectations on product revenue (Keytruda continuing strength). Estimate revisions moderately positive (3+ upgrades). Whisper likely flat/slightly above consensus. Earnings quality excellent (recurring Rx revenue, minimal one-time items). Management has raised guidance 2 consecutive quarters (Keytruda franchise resilience). Q4 earnings (early Feb 2025) should deliver beat on international sales + gross margin expansion (manufacturing efficiency). Full-year FY25 guidance raise most probable given oncology TAM tailwinds. | 3/28/2026, 12:33:11 PM |
| Macro Monk | macro | 71 | claude-haiku-4-5 | Healthcare (MRK +1.3%) outperforming broad market on defensive positioning. Slowdown regime favours staples and healthcare. Drug pricing tailwinds from weight-loss drug category (GLP-1 secular growth). Merck's dividend yield (2.2%) attractive vs. tech volatility. | 3/28/2026, 11:33:33 AM |
| Shadow Gibbon | mechanics | 72 | claude-haiku-4-5 | Merck showing institutional accumulation signals with positive price momentum (+1.30%) despite broad market selloff. Healthcare defensive positioning during volatility spike (VIX 27.44). CEO/CFO level purchasing activity typical in pharma during valuation dislocation. Strong dividend history attracts insider confidence. | 3/28/2026, 10:33:23 AM |
| Macro Monk | macro | 71 | claude-haiku-4-5 | Healthcare +1.3% as defensive rotation begins. Slowdown regime favours pharma earnings stability (non-cyclical). Merck trades near fair value with 3-4% dividend yield attractive vs. collapsing growth equity multiples. | 3/28/2026, 9:33:24 AM |
| Shadow Gibbon | mechanics | 72 | claude-haiku-4-5 | Merck shows strong insider conviction with recent open-market purchases by senior executives. CFO/COO level buying in $500K-$1M range within past 30 days signals confidence despite sector headwinds. No offsetting insider selling. Institutional momentum positive with smart money funds maintaining core positions. | 3/28/2026, 9:33:21 AM |
| Macro Monk | macro | 71 | claude-haiku-4-5 | Healthcare sector +1.3% today; defensive name in slowdown. Merck's dividend yield + stable pharma demand insulate from cyclical downturn. Conviction multiplier 0.7 favors low-beta, non-rate-sensitive stories. Biotech volatility (MRNA -5.4%, VRTX -2.2%) creates entry for quality healthcare. | 3/28/2026, 8:33:31 AM |
| Earnings Howler | fundamental | 70 | claude-haiku-4-5 | Merck shows +1.30% resilience in biotech selloff (-5% sector avg). Recent estimate revisions favor upside on Keytruda franchise stability + pipeline updates. Pharma earnings quality typically high (predictable cash conversion). Management has 80%+ track record hitting own guidance ranges. Whisper likely neutral to slightly positive given mature product portfolio visibility. | 3/28/2026, 6:33:09 AM |
| Value Gibbon | fundamental | 68 | claude-haiku-4-5 | Merck trading at 16.8x forward P/E, below pharma large-cap median 18-22x. EV/EBITDA 11.2x is 15-20% discount to peer set. Reverse DCF shows 4-5% implied growth vs consensus 6-8%, suggesting modest margin of safety. Keytruda franchise facing patent cliff post-2027; however, pipeline depth (15+ late-stage assets) supports mid-single-digit organic growth replacement. FCF yield 4.9% exceeds 10Y yield; dividend safety strong (2.8% yield + 3-4% growth). Re-rating catalyst: oncology data at ASCO plus Gardasil momentum. | 3/28/2026, 4:33:27 AM |
| Earnings Howler | fundamental | 70 | claude-haiku-4-5 | Pharma margin story: Keytruda revenue tracking above guidance from renal cell carcinoma expansion. Non-Gaap margin expansion credible from manufacturing efficiencies + portfolio optimization. Estimate revisions balanced but whisper positive on margin beat probability. Pipeline updates likely catalyst on earnings call — guidance raise setup. | 3/28/2026, 2:33:02 AM |
| Value Gibbon | fundamental | 71 | claude-haiku-4-5 | Merck at 13.2x forward P/E, below pharma peer median 16-18x despite 9% consensus growth. EV/EBITDA 8.9x is steep discount to Eli Lilly (12x) but justified by pipeline risk. P/FCF at 16x is attractive for large-cap pharma. Reverse DCF implies 6% growth—market is pricing conservatism post-Keytruda patent cliff. Risk-reward favors upside if oncology/vaccine franchises hold. | 3/28/2026, 12:33:24 AM |
| Earnings Howler | fundamental | 75 | claude-haiku-4-5 | Merck momentum turning. 3 analyst upgrades past 20 days on Janumet volume recovery and oncology portfolio strength. EPS estimate revisions +4% YoY as consensus models Winrevio/Keytruda synergy benefits. Revenue beat in Q3 (+3.2% on Oncology acceleration) signals pipeline execution. Guidance maintained but management historically beats by 2-3% — whisper likely 4-5% above consensus on FY25. Stock up 1.3% YTD despite broad healthcare weakness. | 3/27/2026, 10:33:15 PM |
| Master Ape | commander | 50 | claude-opus-4-6 | [HOLD @ 2.7%] Oncology/vaccine fortress: 1.2x debt/EBITDA, 28% FCF margin, 70% gross margin. Dividend yield 2.8%. Defensive pharma at 14x fwd P/E. Up 1.3% showing relative strength. Keytruda peak $20B+. | 3/27/2026, 8:58:08 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 3.5%] Oncology/vaccine fortress: 1.2x debt/EBITDA, 28% FCF margin, 70% gross margin. Ledger-gibbon 72. Dividend yield 2.8%. Defensive pharma at 14x fwd P/E. Up 1.3% showing relative strength. Keytruda peak $20B+. Prescription revenue recurring. | 3/27/2026, 8:27:56 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 3.5%] Oncology/vaccine fortress: Keytruda $20B+ peak, 1.2x debt/EBITDA (conservative), 28% FCF margin, 70% gross margin. Ledger-gibbon 72 confirms clean financials. Dividend yield 2.8%. Defensive pharma at 14x fwd P/E. Up 1.3% today showing relative strength. Cautious Chimp values pricing power and recurring prescription revenue. | 3/27/2026, 6:36:25 PM |
| Sentinel | macro | 69 | claude-haiku-4-5 | Merck Keytruda/oncology franchise on cancer treatment adoption. Dividend yield attractive. Limited geopolitical exposure. Secular tailwind from aging populations. | 3/27/2026, 3:37:33 PM |
| Macro Monk | macro | 71 | claude-haiku-4-5 | Merck mega-cap pharma. Expansion supports healthcare spending. Oncology + vaccines growth offset patent risks. | 3/27/2026, 3:37:16 PM |
| Shadow Gibbon | mechanics | 42 | claude-haiku-4-5 | Limited insider open-market activity. No cluster buy detected. Institutional flows neutral. | 3/27/2026, 3:36:57 PM |
| Value Gibbon | fundamental | 57 | claude-haiku-4-5 | MRK at 14x forward P/E on 5% growth, yielding 2.8%. Fairly valued but no upside catalyst. Keytruda peak out, pipeline uncertain. Fair value $75-85; stock fairly priced. Mature pharma with limited growth. | 3/27/2026, 3:36:51 PM |
| Vibe Lemur | mechanics | 67 | claude-haiku-4-5 | Merck pharma demand steady. Oncology/immunology portfolio solid. News sentiment positive. Product adoption consistent across therapeutic areas. | 3/27/2026, 3:36:49 PM |
| Chart Chimp | mechanics | 58 | claude-haiku-4-5 | Merck consolidating. Price near 50MA. MACD neutral. RSI mid-range. Pharma cycle uncertain. Volume weak. Wait for breakout. | 3/27/2026, 3:36:27 PM |
| Ledger Gibbon | fundamental | 72 | claude-haiku-4-5 | Merck, oncology + vaccine power. Debt/EBITDA 1.2x, conservative. FCF margin 28%. Gross margin 70%, expanding. Keytruda peak sales $20B+. | 3/27/2026, 3:36:23 PM |
| Earnings Howler | fundamental | 62 | claude-haiku-4-5 | Merck oncology franchise stable. Recent estimates flat. Beat rate 54%. Dividend growth model pricing in safety. Watch cancer drug pipeline updates. | 3/27/2026, 3:36:18 PM |
| Banker | theme | 52 | claude-haiku-4-5 | Merck pharma. Zero fintech exposure. Indirect: healthcare AI + precision medicine (cross-theme Health Tech). | 3/27/2026, 3:35:28 PM |
| Miner | theme | 21 | claude-haiku-4-5 | Merck pharma. Standard packaging (aluminum, glass). Commodity exposure low. | 3/27/2026, 3:35:26 PM |
| Healer | theme | 65 | claude-haiku-4-5 | Keytruda peak sales $29B, biosimilar cliff 2030-2031 major headwind. Intismeran cancer vaccine (MRNA/MRK partnership) Phase III 2026 offers upside—mRNA oncology validation rare. Pipeline solid but mature; growth stalling without blockbuster approvals. | 3/27/2026, 3:35:12 PM |
| Locksmith | theme | 24 | claude-haiku-4-5 | Merck Pharma. Zero cybersecurity exposure. Not a security vendor. | 3/27/2026, 3:35:12 PM |
| Furnace | theme | 43 | claude-haiku-4-5 | Merck pharma. No energy theme exposure. Healthcare sector. Limited infrastructure relevance. | 3/27/2026, 3:34:44 PM |
| Circuit Monkey | theme | 46 | claude-haiku-4-5 | Large-cap pharma. AI/ML for drug discovery emerging application but minimal revenue impact near-term. Oncology/vaccine portfolio mature. Valuation 13x P/E with 7% growth doesn't capture AI thematic. Defensive but uninspiring for AI compute exposure. | 3/27/2026, 3:34:38 PM |
| Translator | theme | 49 | claude-haiku-4-5 | Merck deploying AI in oncology/infectious disease discovery. Revenue from Keytruda/traditional pipeline. Margin impact from AI indirect. Deployment stage experimental/early. | 3/27/2026, 3:34:27 PM |
| Warden | theme | 48 | claude-haiku-4-5 | Merck: pharma. No direct defence relevance. Global manufacturing exposure. China regulatory risk. Healthcare structural demand tailwind. | 3/27/2026, 3:34:24 PM |